KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
AcquisitionsAsset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in ReceivablesChange in TaxesDeferred TaxesDepreciation & Amortization (CF)Depreciation and DepletionDivestmentsDividends Paid - CommonExchange Rate EffectFree Cash FlowGains from Investment SecuritiesLong-Term Debt RepaymentsNet Cash FlowNet IncomeOther Working Capital ChangesOther financing activitiesShare-based CompensationShares IssuedShort-Term Debt issuances
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Elevance Health (ELV) Deferred Taxes (2016 - 2025)

Elevance Health (ELV) has disclosed Deferred Taxes for 17 consecutive years, with -$322.0 million as the latest value for Q4 2025.

  • On a quarterly basis, Deferred Taxes fell 177.59% to -$322.0 million in Q4 2025 year-over-year; TTM through Dec 2025 was -$279.0 million, a 25.4% increase, with the full-year FY2025 number at -$279.0 million, up 25.4% from a year prior.
  • Deferred Taxes was -$322.0 million for Q4 2025 at Elevance Health, down from $269.0 million in the prior quarter.
  • In the past five years, Deferred Taxes ranged from a high of $269.0 million in Q3 2025 to a low of -$322.0 million in Q4 2025.
  • A 5-year average of -$51.4 million and a median of -$68.5 million in 2022 define the central range for Deferred Taxes.
  • Peak YoY movement for Deferred Taxes: plummeted 1400.0% in 2021, then soared 220.09% in 2025.
  • Elevance Health's Deferred Taxes stood at $228.0 million in 2021, then tumbled by 75.88% to $55.0 million in 2022, then plummeted by 538.18% to -$241.0 million in 2023, then surged by 51.87% to -$116.0 million in 2024, then crashed by 177.59% to -$322.0 million in 2025.
  • Per Business Quant, the three most recent readings for ELV's Deferred Taxes are -$322.0 million (Q4 2025), $269.0 million (Q3 2025), and -$52.0 million (Q2 2025).